Apr 11 |
Nasdaq Jumps 250 Points; Crude Oil Down 1%
|
Apr 11 |
Why Aptevo Therapeutics Stock Is Cratering
|
Apr 11 |
Aptevo Therapeutics slumps after discounted equity raise
|
Apr 11 |
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
|
Apr 10 |
Aptevo Therapeutics Provides Pipeline Update
|
Mar 18 |
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
|
Mar 7 |
Why Is Immuno-Oncology Focused Aptevo Therapeutics Stock Trading Higher On Thursday?
|
Mar 7 |
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
|
Mar 5 |
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
|
Mar 4 |
Aptevo Therapeutics down 13%, will effect 1-for-44 reverse stock split
|